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Both preeclampsia and the HELLP syndrome have their origin in the placenta. The aim of this study is to review genetic factors
involved in development of preeclampsia and the HELLP syndrome using literature search in PubMed. A familial cohort links
chromosomes 2q, 5q, and 13q to preeclampsia. The chromosome 12q is coupled with the HELLP syndrome. The STOX1 gene, the
ERAP1 and 2 genes, the syncytin envelope gene, and the −670 Fas receptor polymorphisms are involved in the development of
preeclampsia. The ACVR2A gene on chromosome 2q22 is also implicated. The toll-like receptor-4 (TLR-4) and factor V Leiden
mutation participate both in development of preeclampsia and the HELLP syndrome. Carriers of the TT and the CC genotype
of the MTHFR C677T polymorphism seem to have an increased risk of the HELLP syndrome. The placental levels of VEGF
mRNA are reduced both in women with preeclampsia and in women with the HELLP syndrome. The BclI polymorphism is
engaged in development of the HELLP syndrome but not in development of severe preeclampsia. The ACE I/D polymorphism
affects uteroplacental and umbilical artery blood flows in women with preeclampsia. In women with preeclampsia and the HELLP
syndrome several genes in the placenta are deregulated. Preeclampsia and the HELLP syndrome are multiplex genetic diseases.
1. Introduction
Preeclampsia is a multisystemic disorder in pregnancy with
de novohypertension andproteinuria occurring after the 20th
gestational week and is characterised by hypertension and
proteinuria, with or without oedema.The condition is associ-
ated with a reduced plasma volume, hemoconcentration, and
increased vascular resistance. One of the chief targets is the
kidneys and the clinical picture is dominated by hypertension
and proteinuria [1–3]. The clinical findings of preeclampsia
can manifest as either a maternal syndrome (hypertension
and proteinuria with or without other multisystem abnor-
malities) or fetal syndrome (fetal growth restriction, reduced
amniotic fluid, and abnormal oxygenation) [3].The condition
may cause serious maternal and fetal complications [3].
Women with preeclampsia may develop the HELLP syn-
drome (haemolysis, elevated liver enzymes, and low platelet),
which occurs in 0.5% to 0.9% of all pregnancies and in 10%
to 20% of women with severe preeclampsia. The syndrome
may be complete or incomplete.Themajority of women with
the HELLP syndrome have hypertension and proteinuria
but the condition may also occur without these [4]. Typical
clinical symptoms of the HELLP syndrome are right upper
abdominal quadrant or epigastric pain, nausea, and vomiting.
The upper abdominal pain may be fluctuating, colic-like. Up
to 30–60% has headache and about 20% visual symptoms.
In the postpartum period the HELLP syndrome usually
develops within the first 48 hours in women who have had
proteinuria and hypertension prior to delivery. Excessive
weight gain and generalized edema precede the syndrome in
more than 50% of the cases [4]. However, it is important to
recognize thatwomenwith aHELLP syndrome alsomay have
unspecific symptoms, subtle signs, or viral syndrome-like
symptoms which should not be overlooked. Many women
report a history ofmalaise some days before presentation.The
HELLP syndrome may cause different maternal, fetal, and
neonatal complications which may be serious [4].
Preeclampsia and the HELLP syndrome present as symp-
tomless placental conditions in the first hand and then as
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a maternal syndrome with lesions in different organs and
various clinical symptoms [5].
Preeclampsia may occur without a fetus in the case of
hydatidiform mole [6]. It is established that preeclampsia
originates in the placenta [3, 7, 8]. It is conceivable that the
HELLP syndrome also is a placenta-dependent condition
[9, 10]. Following delivery of the placenta the maternal symp-
toms and signs of preeclampsia often disappear but a pro-
tracted course of a severe HELLP syndrome is not unusual
[11].
A variety of molecular factors are involved in the patho-
physiology of preeclampsia and the HELLP syndrome. The
aim of this publication is to present a review and a com-
prehensive description of the genetic factors involved and to
suggest modes of action in development of preeclampsia and
the HELLP syndrome.
2. Search Strategy
An unsystematic search in PubMed was conducted by using
the search words: “preeclampsia” or “HELLP” combined with
“etiology,” or “gene” or combined with risk factors, respec-
tively (2000–2013). Abstracts were read and the publication
cited if it was considered adequate.
3. Risk Factors for Preeclampsia and
the HELLP Syndrome
Several risk factors have been identified with increased risk
of preeclampsia. Preeclampsia is generally regarded as a
disease of the first pregnancy.The risk factors include chronic
hypertension, renal diseases, obesity and insulin resistance,
diabetes mellitus, preexisting thrombophilia, family history
of preeclampsia, and smoking [3]. High body mass index
(BMI) and metabolic syndrome 6 months postpartum were
associated with preeclampsia but hardly with HELLP [12].
Most white womenwithHELLP aremultiparous.Women
with a HELLP syndrome are more likely than those in the
control group to be >35 years old (33% compared with
22%), be nulliparous (67% compared with 43%), have had
a previous gestational hypertensive disorder (9% compared
with 7%), and have a multiple pregnancy (7% compared with
2%) [13].
The risk of preeclampsia increases in those who have
limited sperm exposure with the same partner before con-
ception.Most epidemiologic studies demonstrate that regular
sexual intercourse of an extended period reduces the risk
[14, 15]. Women with a history of abortion who conceived
again with the same partner had nearly half the risk of
preeclampsia compared to women without a history of abor-
tion. In contrast, women with an abortion history who con-
ceived with a new partner had the same risk as women
without a history of abortion [16].
3.1. The “Root Cause”. Preeclampsia and the HELLP syn-
drome both originate in the placenta [17]. The “root cause”
of preeclampsia is thought to be reduced placental perfusion
[18]. It has been demonstrated that impaired extra villous
trophoblasts (EVTs) invasion in the decidua and the spiral
arteries and insufficient spiral artery remodeling may take
place both in women with preeclampsia and in women with a
HELLP syndrome [19]. Reduced placental perfusion interacts
with preexisting maternal disorders, such as hypertension,
renal disease, overweight, diabetes mellitus, obesity, lipid
abnormalities, and insulin resistance. This will affect the
maternal susceptibility to preeclampsia because it liberates
bioactive factors which pass through the intervillous space
into thematernal circulation inducing an inflammatory reac-
tion and endothelial dysfunction [20–22].
HELLP and preeclampsia become clinically manifest
during the second (early-onset form) or third trimester (late-
onset form) of pregnancy but the initiating event occurs
much earlier in gestation [23]. The resultant symptomatic
second stage of preeclampsia, thematernal syndrome, usually
develops after the 20th gestational week [8, 24]. The HELLP
syndrome is also associated with widespread organ damage
with different clinical signs in the second stage [4, 10].
However, implantation disorders can be detected in the
first trimester, before 12 to 20 weeks’ gestation, when the deep
invasion of EVT and spiral artery remodeling occur and prior
to failed vascular remodeling of the spiral arteries necessary
to reduce placental perfusion [22, 25]. In some cases of
preeclampsia and a HELLP syndrome aberrant restructuring
of the uterine spiral arteries by invading trophoblasts between
weeks 8 and 12 of gestation ultimately causes poor placental
perfusion and placental ischemia [26]. Thus, factors which
increase the risk of preeclampsia and are associated with
abnormal implantation in early pregnancymight be the “real”
“root cause” of preeclampsia [22, 25].
4. Genetic Considerations
4.1. Epidemiologic Studies. It has been recognised for many
years that preeclampsia has different genetic components
[27]. Both maternal and fetal genes appear to play etiolog-
ical roles. Evidence for a role for paternally inherited fetal
genomes comes from an analysis of data from the Norwegian
Medical Birth Registry from 1967 to 1992, which identified
almost 400,000womenwho had had at least two pregnancies.
It was possible from the records to distinguish between a
pregnancy with the same parents and those where themother
or the father differed in the second pregnancy [28]. In the first
pregnancies the risk of preeclampsia was above 3%, slightly
increasingwithmother’s age.The riskwas 1.7% among second
pregnancies inmothers who had their second pregnancywith
the same partner and 1.9% among second pregnancies in
mothers who had changed their partner since the first preg-
nancy [28]. Men who were born from a preeclampsia preg-
nancywere at risk of fathering a preeclampsia pregnancy [29].
First degree female relatives of womenwith preeclampsia had
a 5-fold higher risk and seconddegree relatives a 2-fold higher
risk of developing preeclampsia thanwomenwithout a family
history of preeclampsia [30]. Studies of familial aggregation
of preeclampsia indicate that genetic factors may contribute
more than 50% of the variability in liability to preeclampsia
[31, 32].
Women with a history of HELLP are at increased risk
of preeclampsia (22–28%) and a HELLP syndrome (14–24%)
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in subsequent pregnancies, suggesting related pathogenic
mechanisms [33, 34]. Sisters and children of a woman who
has sustained a HELLP syndrome have increased risks of
developing a HELLP syndrome in pregnancy [35].
5. Candidate Genes
In 1999 the results of a genome-wide scan of Icelandic fami-
lies, which included 124 pedigrees of 343 women affected by
preeclampsia, were published byArngr´ımsson et al.The study
revealed a maternal susceptibility locus for preeclampsia on
chromosome 2p13 [36]. A genetic linkage to chromosomes
2q, 5q, and 13 q was demonstrated in an Australian/New
Zealander familial preeclampsia cohort [37]. In a study by
Lachmeijer et al. a genome-wide scan of Dutch affected
sib-pair families uncovered a peak on chromosome 12q
which was associated with the HELLP syndrome. It increased
to a lod score of 2.1 in the HELLP families and almost
disappeared in families with preeclampsia. This means that
the HELLP syndrome and preeclampsia have a different
genetic background [35].
Susceptibility genes at the 5q gene locus were also cen-
tered in a spectrum of families in a Norwegian preeclampsia
cohort (1,139 cases and 2,269 controls) using (SNP) genotyp-
ing [37].There was also evidence of a genetic association with
preeclampsia for the endoplasmatic reticulum aminopepti-
dases 1 and 2 (ERAP1 and 2) genes. The ERAP1 and ERAP2
genes encode enzymes that play roles in blood pressure
regulation via involvement of the renin-angiotensin system in
addition to the innate immune system [37]. The ERAP1 gene
cleaves the cell surface receptors for the proinflammatory
cytokine interleukin-1 (IL-1), IL-6, and the tumor necrosis
factor𝛼 (TNF-𝛼) thereby downregulating their signaling.The
ERAP1 gene can therefore have proinflammatory effects [37].
An association between the susceptibility activin recep-
tor type 2 gene (ACVR2A) on chromosome 2q22 and
preeclampsia (𝑛 = 1139) was demonstrated in the Nor-
wegian cohort. DNA samples from 1139 cases (women with
one or more preeclamptic pregnancies) and 2269 controls
(women with normal pregnancies) were genotyped using
the Applied Biosystems SNPlex high-throughput genotyping
assay [38]. The fact that populations with different ances-
tors (Iceland/Norway-Australia/New Zealand) demonstrate
a common maternal preeclampsia susceptibility locus on
chromosome 2q22 may suggest a general role of this locus in
the pathophysiology of preeclampsia.TheACVR2A genemay
affect the activin A activity which is involved in EVT invasion
in the decidua and the spiral arteries as well as in remodeling
of the spiral arteries [38].
Goddard et al. conducted a large scale study evaluating
775 single nucleotide polymorphisms (SNPs) in 190 genes in
women with preeclampsia (𝑛 = 294) and their offspring (𝑛 =
324) [39]. SNPdiscoverywas performed byDNA sequencing,
and genotyping was carried out in a high-throughput facility
using the MassARRAY TM System. The most significant
findings for an association with preeclampsia were the
collagen, type I, alpha 1 (COL1A1) and IL1A genes for the
maternal genotype and the plasminogen activator, urokinase
receptor gene (PLAUR gene) for the offspring genotype.
Notably, common candidate genes for preeclampsia, includ-
ing methylene-tetrahydrofolate reductase (MTHFR) and
nitric oxide synthase 3 (NOS3), were not significantly asso-
ciated with preeclampsia [39].
Buimer et al. performed a study of the gene expression
in placental tissues from normotensive pregnant women and
women with preeclampsia and a HELLP syndrome. Firstly,
comparison of Serial Analysis of Gene Expression profiles
of 28 weeks’ control placenta (available after idiopathic pre-
mature delivery) to a HELLP/preeclampsia placenta matched
for gestational age identified 404 differentially expressed
transcripts. Secondly, using sequential PCR, the expression
levels of 37 of these transcripts in the placentas of healthy
pregnantwomen (𝑛 = 36) and in the placentas of womenwith
preeclampsia and a HELLP syndrome (𝑛 = 22) were anal-
ysed. Thirdly, nearest centroid classification determined the
HELLP specific molecular signature consisting of the upreg-
ulated expression of genes encoding the vascular endothelial
growth factor receptor (FLT1), leptin (LEP), pappalysin 2
(PAPPA2), andWWdomain containing transcription regula-
tor 1 (WWTR1) combined with downregulated expression of
the genes encoding cadherin-associated protein (CTNNAL),
glutathione S-transferase pi (GSTP1), and calgranulin A
(S100A8).This set discriminates theHELLPplacenta from the
placenta of healthy women and the placenta of women with
preeclampsia with a 24% misclassification rate, independent
of known risk factors like parity and ethnicity [23].
6. Some Selected Genes and Occurrence of
Preeclampsia and HELLP
In the following the influences of different genes on develop-
ment of preeclampsia and the HELLP syndrome according
to various publications are presented. Genome-wide associ-
ation studies (GWAS) have disclosed susceptibility genes for
preeclampsia. The results seem compatible with the assump-
tions that unfavourable gene variants and interactions
between genes regulating maternal-fetal interactions are
involved in development of preeclampsia. Table 1 summarizes
selected gene effects on preeclampsia and the HELLP syn-
drome obtained after unsystematic search in PubMed.
7. The STOX1 Gene
The 10q22 chromosomal region with genomic linkage to
preeclampsia in Dutch females shows a parent-of-origin
effect with maternal transmission of Y153H susceptibility
allele of the STOX1 gene [55]. The STOX1 gene, which is
placentally expressed, was identified as a candidate gene for
preeclampsia (𝑛 = 157) in a Dutch population [56]. Two
studies (2007) in both a Dutch and a Finnish population did
not support or confirm that the STOX1 gene was involved in
development of preeclampsia [57, 58]. However, the roles of
STOX1 on trophoblasts dysfunction have been confirmed in
several studies.The STOX1 gene is a key player in trophoblast
dysfunction underlying early-onset preeclampsia [56, 59–61].
There does not seem to be any study which focuses on the
STOX1 gene and development of the HELLP syndrome.
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Table 1: Gene types connected to preeclampsia and the HELLP syndrome-mode of actions.
Gene Effect on preeclampsia or the HELLP syndrome References
The STOX1 gene A key player in trophoblast dysfunction underlying early-onset preeclampsia [40]
Syncytin envelope gene A reduced expression may disturb placental function and increase rate of apoptosisin cytotrophoblasts
[41]
MBL gene polymorphism
Excessive MBL-mediated trophoblast damage may cause insufficient EVT invasion
of the spiral arteries. Maternal heterozygosity at codon 54 of the MBL B allele
protects against preeclampsia and HELLP
[42]
Factor V Leiden mutation Increase risk of preeclampsia and HELLP [43, 44]
MTHFR C677T
polymorphism Involved in development of the HELLP syndrome.
[45]
G0210A mutation of factor
II (prothrombin) gene Involved in development of preeclampsia
[46, 47]
The VEGF TT-460 SNP
genotype
Carriers had an increased risk of HELLP syndrome and could play a role in
development of the HELLP syndrome
[48]
ACE I/I/D polymorphism
The renin-angiotensin system is a mediator of the EVT invasion and remodeling of
the spiral arteries.
The ACE I/D polymorphism seemed to affect the uteroplacental and umbilical
artery (UA) blood flows and the recurrence of preeclampsia
[49]
BclI polymorphism of the
GR gene
The BclI polymorphism is associated with development of HELLP syndrome but
not of severe preeclampsia
[50]
Polymorphism of EPHX
gene
High activity genotype in exon 3, which could reflect differences in metabolic
activation of endogenous or exogenous toxic compounds, may have enhanced
susceptibility to preeclampsia
[51]
NFRSF6-670
polymorphism
Homozygous carriers with the -670 AG or GG genotype are more likely to develop
the HELLP syndrome than those homozygous for the wild type of the Fas receptor
(TNFRSF6-670A/A)
[52]
TLFR-4 gene TLR-4 pathway and the innate immune system might be involved in developmentof both early-onset preeclampsia and the HELLP syndrome
[53]
Leptin gene (LEPR) The LEPR gene and its serum level correlate with the leptin concentration inperipheral blood. The LEPR gene is transcribed in the villous and EVTs
[54]
8. The Syncytin Envelope Gene
The creation of the syncytium layer by cytotrophoblasts
is an important step in the placentation process. Syncytin
envelope gene is an essential gene mediating the cytotro-
phoblast cell-cell fusion and differentiation [40, 62, 63].
Decreased syncytin expression in cytotrophoblasts impairs
the syncytiotrophoblast formation [64]. A study by Knerr et
al. included women with preeclampsia (𝑛 = 16), women with
a HELLP syndrome (𝑛 = 6), and healthy pregnant women
(𝑛 = 30). After delivery, mRNA of syncytin, glyceraldehyde-
3-phosphate dehydrogenase, and 𝛽-actin were analyzed in
placental villi with use of quantitative real-time PCR. The
syncytin mRNA levels were significantly lower in the chori-
onic villi in womenwith preterm preeclampsia and inwomen
with the HELLP syndrome than in women with healthy
pregnancies. A reduced placental expression of syncytin
may contribute to altered cell-cell fusion processes in the
placentogenesis and to a disturbed placental function [65].
The placenta was analyzed in a study by Langbein et al.
comprising women with preeclampsia and IUGR (𝑛 = 8)
and women with the HELLP syndrome and IUGR combined
(𝑛 = 8). Total RNA was extracted from 50 to 100mg
of frozen placental tissues by mincing using a Mikro-
Dismembranator (Braun Biotech, Sartorius AG, Goettingen,
Germany) and purified using Trizol1 reagent (Invitrogen,
Karlsruhe, Germany). The syncytin envelope placental gene
expression in women with preeclampsia combined with
IUGR was 5.4-fold lower and in women with the HELLP
syndrome associated with IUGR was 10.6-fold lower along
with a 1.8- and 1.9-fold significant increase in the apoptosis
rate in the cytotrophoblasts compared with control subjects,
respectively.This higher rate of apoptosismay be contributing
to an inflammatory response [66].
9. Mannose-Binding Lectin (MBL)
Gene Polymorphism
Insufficient invasion of the spiral arteries by trophoblast cells
is associatedwith the etiology of preeclampsia and theHELLP
syndrome. Mannose-binding lectin (MBL) is a component
of the innate immune system. The MBL gene is located
on chromosome 10 and is polymorphic at codons 52, 54,
and 57. MBL is present in the spiral arteries, particularly in
those containing endovascular trophoblasts. MBL-mediated
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activation of the complement cascade is an important event
in destruction of invading EVTs [67].
Carriers of the MBL-54 B variant have been reported in
22–28% of European and North American populations [67].
ExcessiveMBL-mediated trophoblast damagewould increase
the possibility of insufficient EVT invasion of the spiral
arteries. The subsequent hypoxia could initiate a sequence of
events culminating in preeclampsia [67].
A study by Sziller et al. comprised women with pree-
clampsia (𝑛 = 51), women with the HELLP syndrome (𝑛 =
81), and healthy pregnant women (𝑛 = 184). DNA was
extracted from buccal swabs of women with preeclampsia,
women with HELLP syndrome, and healthy pregnant con-
trols. Aliquots were tested for a single nucleotide MBL gene
polymorphism at codon 54 by PCR and endonuclease diges-
tion. There was significantly higher number of the TT geno-
type (25%) in women with the HELLP syndrome than in
women with severe preeclampsia (9%) and in healthy (8%)
pregnant women. It was suggested that maternal heterozy-
gosity at codon 54 of the MBL B allele was protective
against development of preeclampsia and HELLP syndrome.
Homozygosity for the wild type allele A of the MBL-54 gene
was more frequent among women with preeclampsia and the
HELLP syndrome. Carriage of the variant B allele was also
protective against development of IUGR in women with both
preeclampsia and HELLP syndrome [67].
10. Factor V Leiden Mutation
Thrombosis and atherosis of the spiral arteries are often found
in the placenta of women with preeclampsia, the HELLP syn-
drome, and IUGR [41, 42]. Women with a HELLP syndrome
also had frequent acute atherosis in spiral arteries invaded by
EVTs and in noninvaded spiral arteries (Robert Pijnenborg,
personal communication). Factor V Leiden mutation is the
cause of resistance to activated protein C which may lead to
intravascular coagulation.
Lin and August performed a meta-analysis on genetic
thrombophilias and preeclampsia assessing the relationship
between the factor V Leiden (1691 G-A) SNP, the methylene
tetrahydrofolate reductase (MTHFR) 677 C-T SNP, and the
prothrombin 20210 G-A SNP in all case-control studies with
data on these polymorphisms [68]. All investigations used
PCR reaction and restriction fragment length polymorphism
analysis of DNA obtained from blood or buccal cells in the
case-control studies. The pooled odds ratio (OR) for the
association of factor V Leiden mutation and all women with
preeclampsiawas 1.81 (95%) confidence interval (95%CI 1.14–
2.87) and 2.24 (95% CI 1.28–3.94) for women with severe
preeclampsia [68].
A publication from 2008 revealed a clear relationship
between factor V Leidenmutation and womenwith a HELLP
syndrome. Genotyping of the thrombophilic mutations was
performed using the LightCycler technology. Maternal het-
erozygosity for factor V Leiden mutation was significantly
more prevalent in women with a HELLP syndrome (𝑛 = 71)
than in healthy control women (𝑛 = 79) (OR 4.45) (Table
2) [69]. No significant association was observed for maternal
prothrombinmutation orMTHFR polymorphism.The study
confirmed that women heterozygous for factor V Leiden have
an increased risk of developing aHELLP syndrome, while the
most frequent mutations of the prothrombin and MTHFR
gene did not play a major role in the pathogenesis [69].
11. MTHFR Polymorphism, Homocysteine,
Preeclampsia, and HELLP
It has been shown that alterations in the methionine homo-
cysteine metabolism may be related to the systemic damage
that leads to the classical clinical picture of preeclampsia
[74]. A recent study evaluates the role of key enzymes in
the methionine-homocysteine metabolism (MHM) in the
physiopathology of preeclampsia. Plasma and placenta from
pregnant women (32 controls and 16 preeclamptic women)
were analysed after informed consent. Protein was quantified
by western blot. RNA was obtained with RNA purification
kit and was quantified by reverse transcriptase followed by
real-time PCR. Identification of the C677T and A1298C
methylene tetrahydrofolate reductase (MTHFR) SNPs and
A2756G methionine synthase (MTR) SNP was performed
using PCR followed by a high-resolution melting analysis.
It was shown that women who develop preeclampsia are
clinically distinguishable at 11–14 weeks of gestation. Key
enzyme RNA expression is increased in preeclamptic women
but this change is not reflected at the protein content.
These results highlight a potential role of the MHM as a
compensation mechanism in the presence of low levels of 2-
methoxyestradiol (2-ME) [74].
The MTHFR gene plays a role in the metabolism of
homocysteine. Nagy et al. conducted experiments on iso-
lated DNA samples from the blood of women with severe
preeclampsia (𝑛 = 101), women with the HELLP syndrome
(𝑛 = 63), and healthy pregnant women (𝑛 = 73).TheMTHFR
C677T polymorphism was determined by quantitative real-
time PCR. The mutant T allele was found in 45% of women
with the HELLP syndrome, in 32% of the healthy pregnant
women, and in 30% of women with severe preeclampsia [43].
The results showed no difference in the distribution of the
MTHFR C677T genotypes between the healthy controls and
women with preeclampsia. In the study, however, there was
a substantial difference between the incidences of MTHFR
677T genotype among HELLP syndrome women and the
other two study groups. Thus, the MTHFR C677T poly-
morphism might be involved in development of the HELLP
syndrome [43].
12. Factor V Leyden Mutation,
G0210A Mutation in the Factor II
(Prothrombin) Gene, and MTHFR in
Women with Thrombophilia
The mutation of the prothrombin gene is associated with an
increased risk of both venous and arterial thromboembolism.
Severe preeclampsia, the HELLP syndrome, and IUGR are
associated with intervillous and/or spiral artery thrombosis
and inadequate placental perfusion. A congenital throm-
bophilia disorder is the G0210A mutation in the factor II
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Table 2: OR impact on preeclampsia and HELLP.
Gene variant Preeclampsia compared to HELLP compared to Number OR (95% CI) References
Factor V Leiden mutation Healthy pregnancy 71 4.45 (1.31–15.31) [69]
Factor Leiden mutation
169G-A SNP
Healthy pregnancy 1,798 1.81 (1.14–2.87) [70]
Factor V Leiden mutation Healthy pregnancy 32 2.29 (0.56–9.32) [45]
Factor II prothrombin mutation Healthy pregnancy 32 6.03(0.65–47.54)
[45]
Three mutations Healthy pregnancy 7,522 1.84 (1.14–2.87) [71]
MTHFR 677C-T SNP Healthy pregnancy 2,250 1.01 (0.79–1.29) [1]
VEGF C −460T SNP Healthy pregnancy 71
Adjusted
OR 3.95
(1.51–6.08)
[72]
VEGFG 405C SNP Healthy pregnancy 71
Adjusted
OR 3.67
(1.05–1.75)
[72]
BclI polymorphism of GR gene Healthy pregnancy 17
Adjusted
OR 2.89
(1.45–5.74)
[49]
BclI polymorphism of GR gene Severe preeclampsia 150 2.56 (1.45–5.74) [49]
Polymorphism of EPHX gene Healthy pregnancy 87 2.0 (1.2–3.7) [49]
Fas TNFRSF6 gene Healthy pregnancy 84 2.7 (1.2–5.9) [51]
TLR-4 gene Healthy pregnancy 177 4.1 (1.7–9.8) [52]
Combined TLR-4 and NOD2 variant and high
levels of IL-6
Healthy pregnancy 177 6.9 (2.1–23.2) [52]
I/II genotype of LEPR gene Healthy pregnancy 40 3.8 (0.8–18.0) [73]
LEPR 223G allele LEPR 23A/Agenotype 24 1.92 (1.07–3.41) [54]
(prothrombin) gene which may lead to higher prothrombin
production and to an increased risk of thrombosis [75].
A case-control study was performed by Benedetto et al.
comprising women with preeclampsia (𝑛 = 111) and women
with normal pregnancies (𝑛 = 111) matched for age and
parity without previous thromboembolic disorders [45]. The
women were tested for the A1691G mutation in the factor
V Leyden mutation and the G20210A mutation of the factor
II (progesterone) genes was amplified by PCR with Perkin
Elmer Gene Amp 2400 (New Jersey, USA). Factor V Leiden
mutation was found in a few women with preeclampsia and
in healthy controls. Factor II G20210A mutation was also
detected in some women with preeclampsia [45]. In the
subgroup of women with the HELLP syndrome (𝑛 = 32),
factor V Leiden mutation was detected in 3 women (9.3%)
and factor II G20210A in 2 (6.2%). Thus, the prevalence of
factor V Leyden mutation OR 2.29 (0.56–9.32) and factor
II mutations OR 6.03 (0.65–47.54) was increased in women
with preeclampsia. The thrombophilia mutations may inter-
act with other pathogenic factors to determine the clinical
features of the diseases and its complications [45].
In another study by Kupferminc et al. women were tested
several days after delivery for the mutation of adenine to
guanine at nucleotide 506 in the factor V gene (factor V
Leiden), the mutation of cytosine to thymine at nucleotide
677 in the gene encoding MTHFR, and the mutation of
guanine to adenine at nucleotide 20210 in the prothrombin
gene the prothrombin gene G20210A mutation [76]. The
G20210Amutation was found to occur more often in women
with complications such as preeclampsia (𝑛 = 11) than in
women without complications (𝑛 = 3) (10% versus 3%, resp.).
Overall, 57 of the 110 women with obstetrical complications
(52 percent) had at least one of the three thrombophilic
mutations, as comparedwith 19 of the 110womenwith normal
pregnancies (17 percent) (OR 5.2; 95% 2.8 to 9.6) [76].
13. Vascular Endothelial Growth Factor
(VEGF), Preeclampsia, and HELLP
VEGF is produced by cytotrophoblasts and villous syncy-
tiotrophoblasts in the placenta [46]. VEGF is an endothelial
cell-specific growth factor and a regulator of physiological
and pathological angiogenesis [47]. Nagy et al. performed
a study to determinate three VEGF SNPs. The allele and
genotype frequencies of VEGF C −460T SNP were deter-
mined in the maternal blood. DNA was isolated by using
a silica adsorption method. The SNPs were determined by
quantitative real-time PCR and melting curve analysis using
LightCycler. Both carriers of the −460TT and the +405CC
genotype of VEGF receptor genotype seemed to have an
increased risk of development of a HELLP syndrome (𝑛 =
71) compared to healthy controls (𝑛 = 93). There were
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significant differences in the allele and genotype frequencies
of VEGF C −460T SNP between the two study groups. The T
allele was present in 71% in the HELLP group and in 54% of
the healthy controls. The TT genotype occurred significantly
more frequently in the HELLP group than in the control
group (45% versus 22%). The TT genotype carriers had an
increased risk of HELLP syndrome, which was independent
of maternal age and primiparity (adjusted OR 3.95) (Table 2).
Although the VEGF G +405C allele and genotype distribu-
tions did not differ significantly between the two groups, the
CC genotype carriers were also found to have an increased
risk of HELLP syndrome after adjustment for maternal age
and primiparity (adjusted OR 3.67) (Table 2). The VEGF C
−2578A SNP was not associated with the HELLP syndrome.
The findings suggest that the VEGF polymorphisms, inter-
acting with other genetic and environmental factors, could
play a role in the development of the HELLP syndrome
[77].
Sgambati et al. performed a study to determine the
expression of VEGF in the placental tissue from pregnancies
complicated by hypertension disorders of different clinical
severity [72]. Placentas from women with gestational
hypertension (𝑛 = 20), preeclampsia (𝑛 = 20), and
preeclampsia with HELLP syndrome (𝑛 = 20) and from nor-
motensive women (𝑛 = 20) were analyzed as a control group
(gestational age comprised between 35 and 38 weeks). An
immunohistochemical technique and a quantitative real-time
PCR analysis to measure mRNA levels were employed. The
levels ofVEGFmRNAwere higher inwomenwith gestational
hypertension and lower in women with preeclampsia with
HELLP syndrome compared to the levels of VEGF mRNA
in control women [72]. The different expression of VEGF in
the placenta of the pathological cases is probably related to
hemodynamic changes that take place in these disorders, in
order to attempt restoration of a normal uteroplacental flow
[48].
14. The Angiotensin-Converting Enzyme
(ACE) I/D Polymorphism
Local prostacyclin stimulates the uteroplacental renin-angio-
tensin system (RAS) and induces release of angiotensin-II
(Ang-II) from trophoblasts.This improves the uteroplacental
blood flow by increasing perfusion pressure and by forming
an extra stimulus of prostacyclin and nitric oxide (NO)
release from uteroplacental vessels [48, 78].
The renin-angiotensin system is one of the mediators of
the EVT invasion and remodeling of the spiral arteries. In a
study women with preeclampsia (𝑛 = 106) were genotyped
for theACE I/D polymorphism.GenomicDNAwas extracted
from leukocytes using aQIAmpBloodKit (QIAGEN,Hilden,
Germany) [79].TheACE I/D polymorphism seemed to affect
the uteroplacental and umbilical artery (UA) blood flows
and the recurrence of preeclampsia. The UA resistance index
was significantly lower in the II genotype, higher in DD,
and intermediate in I/D genotype carriers.The UA pulsatility
index values were significantly higher in the DD group
than in the I/D and II genotype [79]. It was concluded
that in women with a history of preeclampsia the ACE
I/D polymorphism affects both uteroplacental and umbilical
blood flows and the recurrence of preeclampsia [79].
15. The BclI Polymorphism of
the Glucocorticoid Receptor (GR) Gene
The glucocorticoid receptor (GR) gene is the receptor to
which cortisol and other glucocorticoids bind. The GR gene
is expressed in almost every cell in the body and regulates
genes controlling the development,metabolism, and immune
response. A study by Bertalan et al. comprised healthy preg-
nant women (𝑛 = 300), women with severe preeclampsia
(𝑛 = 150), and women with a HELLP syndrome (𝑛 = 17)
[80]. Total genomic DNAwas isolated from peripheral blood
lymphocytes using a QIAamp DNA Blood Mini Kit (Qiagen
GmbH, Hilden, Germany) and the blood spot samples were
denatured by heat inactivation. The BclI and the N363S
polymorphisms of the GR gene were determined by allele-
specific PCR. There were no significant differences in car-
rier and allelic frequencies of the N363S and ER22/23EK
polymorphisms between healthy pregnant women and those
with severe preeclampsia. However, the allelic and carrier fre-
quencies of the BclI polymorphism were significantly higher
in women with HELLP syndrome compared to healthy preg-
nant women (OR 2.89) and compared to those with severe
preeclampsia (OR, 2.56) (Table 2). The observations suggest
that, among pregnant women, the BclI polymorphism is
associated with development of theHELLP syndrome but not
of severe preeclampsia. Interestingly, the BclI carrier status
had a significant impact on clinical laboratory parameters
of women with the HELLP syndrome. The aspartate amino-
transferase (AST), lactate dehydrogenase (LDH), and alkaline
protease (ALP) levels were significantly higher whereas the
platelet count tended to be lower in BclI carriers than in
noncarriers [80].
16. Polymorphism of Microsomal Epoxide
Hydrolase Gene (EPHX)
Genetic polymorphisms have been described in the human
gene encoding for microsomal EPHX. Two of these polymor-
phisms, 113Tyr→His in exon 3 and 139His→Arg in exon 4,
are associated with either a decreased or an increased enzyme
activity, respectively [49]. A study by Zusterzeel et al. from
2001 focused on whether or not the genetic variability in
the EPHX gene could contribute to preeclampsia and the
HELLP syndrome Genomic DNA was isolated from whole
blood using the WizardTM genomic DNA purification kit
(Promega,Madison,WI,USA). Amore frequent high activity
genotype Tyr113→Tyr113 in exon 3 (29%) was found in
women with preeclampsia than in control subjects (16%)
(OR 2.0) (Table 2). In women with a history of preeclampsia
no difference in epoxide hydrolase genotypes was found
betweenwomenwho either did or did not develop theHELLP
syndrome [49]. Women with the high activity genotype in
exon 3, which could reflect differences inmetabolic activation
of endogenous or exogenous toxic compounds, may have
enhanced susceptibility to preeclampsia [49].
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17. Polymorphism of the Fas Receptor
Fas and Fas Ligand (FasL) are classical transmembrane pro-
teins that belong to the tumour necrosis factor receptor
super family (TNFRSF). FasL is localized to both syncytiotro-
phoblasts and cytotrophoblasts in the placental chorionic
villi [50]. FasL and its receptor, Fas, are known to play an
important role in regulation of the immune response. Fas is
highly expressed on activated T cells, B cells, NK cells, and
macrophages [50]. Sziller et al. reported that a single adenine
(A) to guanine (G) polymorphism at position −670 in the
Fas receptor (TNFRSF6) results in decreased Fas synthesis.
A study by Sziller et al. comprised women with a HELLP
syndrome (𝑛 = 84) and normotensive women (𝑛 = 83)
[51]. Cells from the buccal mucosa were obtained by rotating
cotton swab within 1 hour after delivery. Genotype and
allele frequencies were determined by direct counting and
then dividing by number of chromosomes to obtain allele
frequency and by the number of women to obtain genotype
frequencies [51]. It was found that homozygous carriers with
the −670 AG or GG genotype were more likely to develop the
HELLP syndrome than those homozygous for thewild type of
the Fas receptor (TNFRSF6−670A/A) (OR 2.7) (Table 2) [51].
The TNFRSF6−670 polymorphism is linked to decreased
apoptotic potential of maternal T cells due to polymorphism
in the Fas receptor at −670 which is thought to contribute to a
prolonged capacity ofmaternal lymphocytes to recognize and
destroy EVTs during invasion of the decidua and the spiral
arteries which may lead to development of preeclampsia or
HELLP syndrome [51].
18. Maternal TLR-4 and NOD2 Gene
Toll-like receptors (TLR) are considered to be the most
important class of pattern-recognition receptors (PRRs)
involved in host defence against a variety of microbes. TLRs
are central components of the innate immune system [81].
Toll-like receptors (TLRs) are central components of the
innate immune system [81]. The allelic variants of the innate
immune system, the toll-like receptor-4 (TLR-4) and the
NOD2 gene (an apoptosis regulator) variants, were investi-
gated by van Rijn et al. 6months after delivery in primiparous
women with a history of an early-onset preeclampsia (𝑛 =
340) of whom 177 developed the HELLP syndrome; 113
women with an uneventful pregnancy were controls [52].
Genomic DNA was isolated from blood, using standard
commercially available kits (Gentra Systems, Minneapolis,
MN, USA). Two common missense mutations of the TLR-4
gene (GenBank: NM 138554; OMIM: 603030) were detected
by PCR. The highest frequency of the TLR-4 was observed
in women who developed the HELLP syndrome (adjusted
OR 4.1) (Table 2). Combined positivity for any of the TLR-
4 and NOD2 allelic variants and high levels of IL-6 were
6.9-fold more common in women with a history of early-
onset preeclampsia than in healthy pregnant women (OR
6.9) (Table 2) [52]. In women with preeclampsia a persistent
TLR-4 signal could reverse the CD4+CD25bright Treg cell-
mediated immunosuppression [82].Thismeans that the TLR-
4 pathway and the innate immune system might be involved
in development of both theHELLP syndrome and early-onset
preeclampsia [52].
19. Leptin Gene (LEPR)
During pregnancy hormonal readjustment leads to increased
leptin transcription. Women with preeclampsia display sig-
nificantly higher serum leptin levels than healthy pregnant
women. High leptin levels correlated with the blood pressure
values [53]. Chronic hyperlipemia was associated with an
increased release of the vasoconstrictor endothelin as well as
an activation of the sympatric nerve system which may cause
vasoconstriction [83].
The leptin receptor (LEPR) is a member of the super
family of cytokine receptors. The LEPR gene is transcribed
in the villous and EVTs. Its serum level correlates with the
leptin concentration in peripheral blood [84].The leptin gene
polymorphisms were examined in women with preeclampsia
(𝑛 = 40) and in control women (𝑛 = 29) by Muy-Rivera
et al. [73]. Maternal plasma leptin and SLR concentrations
were measured using enzyme immunoassays (Diagnostic
Systems Laboratory, Inc., Webster, Texas, USA). Elevated
leptin concentrations (14.5 ng/mL) were associated with a
3.8-fold increased risk of preeclampsia (OR 3.8) (Table 2)
whereas low soluble leptin receptor (SLR) (<28.5 ng/mL) was
associated with a 6.3-fold increased risk of preeclampsia 6.3-
fold (OR 6.3, 95%CI 1.7–23.2). On the other hand, the I/II
genotype was associated with a 3.8-fold increased risk of
preeclampsia (OR 3.8) (Table 2) [73].
The frequency of LEPR 223AA genotype in women with
severe preeclampsia (𝑛 = 24) and healthy pregnant women
(𝑛 = 107) was analysed by Rigo´ Jr. et al. Peripheral blood
samples taken for routine laboratory investigations were
used for genotyping the two common DNA sequence vari-
ants in exons 4 and 6 of the LEPR gene using the PCR restric-
tion fragment length polymorphism (RFLP). Genomic DNA
was extracted using the standard phenol-chloroform extrac-
tion procedure [54]. Women with the LEPR 223G allele
(223A/G or 223G/G genotype) had almost a doubled risk of
developing severe preeclampsia compared with women with
the 223A/A genotype (adjusted OR 1.92) (Table 2) [54].Thus,
the LEPR gene is associated with increased risk of developing
preeclampsia.
20. MicroRNA (MiRNA)
MiRNAs are noncoding 20–30 bp nucleotide RNAs with neg-
ative regulation functions which control the gene expression
by binding to messenger RNAs and play roles in biological
functions like cell proliferation, differentiation, apoptosis,
cardiovascular disease, and carcinogenesis [85, 86]. The
MiRNAs are abundantly expressed in the placenta. Zhu et al.
found several microRNA clusters on chromosomes 19q13.42,
13q31.3, Xq26.2, Xq26.3, and 14q32.31 (a human imprinted
region) which were expressed differentially in the placenta
of women with preeclampsia. The results showed that in
women with preeclampsia microRNAs were deregulated,
suggesting involvement of microRNAs in the pathogenesis
[87].
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21. Chorionic Villous Samples (CVS) and
Deregulation of Placental Genes
The human placenta is prerequisite for the development of
preeclampsia and the HELLP syndrome. Several studies have
focused on placental genes. Farina et al. analysed chorionic
villous samples (CVS) from the 11th gestational week from
women who developed preeclampsia (𝑛 = 10) and healthy
controls (𝑛 = 50) with microarray. Altered expression was
found among several genes including those involved in inva-
sion of EVT (Titin), in inflammatory stress (Lactotransferrin),
endothelial aberration (Claudin 6), angiogenesis (Vasohibin
1), and blood pressure control (Adducin 1). CVS showed an
aberrant gene profile prior to development of preeclampsia
[88]. Founds et al. performed 160 CVS at 10–12-week gesta-
tion. Thirty-six differentially expressed genes were identified
in the preeclampsia placenta. Decidual gene deregulation was
prominent [89].
22. Microarray Study of
Women with Early-Onset Preeclampsia
and the HELLP Syndrome
Va´rkonyi et al. conducted a microarray study of women
with early-onset preeclampsia and women with the HELLP
syndrome. Placental specimens were obtained by Cesarean
sections from women with early-onset preeclampsia and
womenwith theHELLP syndrome. Placental specimens were
collected after birth from control women who delivered vagi-
nally preterm or at term. After histopathological examina-
tion, fresh-frozen placental specimenswere used formicroar-
ray profiling and validation by quantitative real-time PCR.
Out of the 350 differentially expressed genes in women with
preeclampsia and 554 genes in women with the HELLP
syndrome, 224 genes (including LEP, CGB, LHB, INHA,
SIGLEC6, PAPPA2, TREM1, and FLT1) changed in the same
direction (elevated or reduced) in both syndromes. Enrich-
ment analyses revealed similar biological processes, cellular
compartments, and biological pathways enriched in early-
onset preeclampsia and the HELLP syndrome. However,
some processes and pathways (e.g., cytokine-cytokine recep-
tor interaction) were overrepresented in women with the
HELLP syndrome [90].
In accordance with the altered trophoblast pathophysi-
ology in early-onset preeclampsia, many of the most differ-
entially regulated genes in women with preeclampsia (LEP,
CGB, LHB, INHA, SIGLEC6, PAPPA2, and FLT1) have pre-
dominant or unique expression in the syncytiotrophoblasts
[91].The results of the study by Va´rkonyi et al. may imply that
trophoblastic metabolic signals overactivated the reproduc-
tive axis in womenwith early-onset preeclampsia andwomen
with the HELLP syndrome. Moreover, enrichment analyses
also revealed the overrepresentation of biological processes,
molecular functions, and pathways that are related to utero-
placental vascular insufficiency and placental oxidative stress,
known to play key roles in the pathophysiology of early-onset
preeclampsia [8, 21, 92].
23. Discussion and Future Directions
The present review highlights several of the genetic factors
playing roles in development of preeclampsia and the HELLP
syndrome. A variety of genes are involved which also inter-
act. The mechanisms are very complicated. Gene variants
in the Fas receptor, the VEGF gene, and the coagulation
factor V Leiden mutation are associated with increased
risk of the HELLP syndrome compared to healthy women
[51, 69, 77]. Variants in the Bell polymorphism [93] and
the TLR-4 increased the risk of HELLP significantly more
than the risk of preeclampsia [52]. A weakness of our
publication is that it is an unsystematic review carrying risk
of missing important references. A weakness of many of
the studies is the low number of cases which makes the
genetic evaluation less certain. In addition, different criteria
have been used in the diagnosis of preeclampsia and the
HELLP syndrome. Criteria for incusing and exclusions also
differ in evaluating case-control studies of thrombophilia
[70].
Interestingly, overall gestational age at deliverywas earlier
in the studies in which higher ORs were reported which may
imply a more severe preeclampsia. For example, the cases
of preeclampsia reported by Scholz et al. were delivered at
less than 28 weeks. In this group the factor V Leiden OR for
preeclampsia was 5.7 [44]. In contrast, the cases reported by
De Groot et al. which were delivered at 34-week gestation
no association between preeclampsia and factor V Leiden
mutation was observed [94].
Retrospective studies suggest that the heritable allelic
variations, particularly the uteroplacental renin-angiotensin
system with defective placental vascular development, could
become the cornerstone for the genetics of preeclampsia
[74].
In a study it was shown that decidual dendritic cells (DC)
stained and reacted differently with decidual natural killer
(dNK) cells in women with the HELLP syndrome com-
pared to women with preeclampsia [44]. In another study,
apoptosis, proliferation, and FasL expression were higher
in villous trophoblast in women with the HELLP syndrome
than in the women with preeclampsia and the control group.
Placentas from a preeclampsia group had higher levels of
apoptosis, lower FasL expression, and no difference in pro-
liferation compared with the control group. The findings in
this study suggested different pathophysiologic mechanisms
in development of preeclampsia and the HELLP syndrome
[95].
In the future there is a need of multicenter studies with
a large number of cases using the latest technology, such
as array comparative genomic hybridization and massive
parallel sequencing, to reveal the genetic changes which have
occurred on the whole genome in women with preeclampsia
and the HELLP syndrome. The microarrays with a high
number of SNPs also seem promising.The use of free nucleic
acids is still at the early stage. More studies are needed also to
apply DNA, RNA, and miRNA measurements. It is possible
that amassive parallel sequencingmight contribute to a better
understanding of the pathophysiology of preeclampsia and
the HELLP syndrome.
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